Bosh sahifaCORT • NASDAQ
add
Corcept Therapeutics Incorporated
68,11 $
Seans yopilganidan keyin:(0,00%)0,00
68,11 $
Yopilgan:11-fev, 16:01:40 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
67,54 $
Kunlik diapazon
67,77 $ - 70,27 $
Yillik diapazon
20,84 $ - 71,29 $
Bozor kapitalizatsiyasi
7,14 mlrd USD
Oʻrtacha hajm
830,06 ming
Narx/foyda
53,64
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 182,55 mln | 47,69% |
Joriy xarajat | 133,08 mln | 46,60% |
Sof foyda | 47,21 mln | 50,47% |
Sof foyda marjasi | 25,86 | 1,85% |
Har bir ulushga tushum | 0,41 | 46,43% |
EBITDA | 46,92 mln | 49,37% |
Amaldagi soliq stavkasi | 10,82% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 380,34 mln | 7,07% |
Jami aktivlari | 784,26 mln | 32,02% |
Jami passivlari | 145,42 mln | 9,88% |
Umumiy kapital | 638,84 mln | — |
Tarqatilgan aksiyalar | 104,78 mln | — |
Narxi/balansdagi bahosi | 11,07 | — |
Aktivlardan daromad | 15,54% | — |
Kapitaldan daromad | 18,68% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 47,21 mln | 50,47% |
Operatsiyalardan naqd pul | 73,83 mln | 39,54% |
Sarmoyadan naqd pul | -44,04 mln | 59,81% |
Moliyadan naqd pul | -21,09 mln | -438,61% |
Naqd pulning sof oʻzgarishi | 8,70 mln | 114,36% |
Boʻsh pul | 70,22 mln | 28,78% |
Haqida
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
Tashkil etilgan
13-may, 1998
Sayt
Xodimlar soni
352
